4502 On Other Exchanges
Symbol
Exchange
4502 is not on other exchanges.

takeda pharmaceutical co ltd (4502) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)
\

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. The company operates in three segments: Prescription Drug, Consumer Healthcare, and Other. It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others. The company is also involved in clinical diagnostics, chemical products, and other businesses. Takeda Pharmaceutical Company Limited has a research collaboration with Shattuck Labs, Inc. to explore and develop checkpoint fusion proteins that have the potential to become immunotherapies; and a collaboration alliance with Stanford University. It also has collaboration agreements with Samsung Bioepis Co., Ltd. to jointly fund and co-develop various novel biologic therapies in unmet disease areas; AstraZeneca PLC to develop and commercialize MEDI1341, an alpha synuclein antibody for the treatment of Parkinson's disease; Noile-Immune Biotech Inc. for the research and development of cancer immunotherapy; HitGen Ltd for the DNA-encoded library based drug discovery research; Montreal Neurological Institute to discover and develop treatments for amyotrophic lateral sclerosis; Denali Therapeutics to develop and commercialize therapeutic product candidates for neurodegenerative diseases; Fujifilm to develop regenerative medicine product for heart patients; and Wave Life Sciences Ltd. to discover, develop, and commercialize nucleic acid therapies for disorders of CNS, as well as Drugs for Neglected Diseases initiative. In addition, the company has a licensing agreement with Fimecs, Inc. for the development of novel immuno-oncology therapies; and a clinical collaboration with Nektar Therapeutics to evaluate the combination of NKTR-214 and TAK-659. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

27,230 Employees
Last Reported Date: 05/14/18
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

Presidednt, CEO & Representative Director
Total Annual Compensation: ¥495.0M
Chief Medical & Scientific Officer and Direct...
Total Annual Compensation: ¥263.0M
Compensation as of Fiscal Year 2016.
takeda pharmaceutical co ltd
Takeda Pharmaceutical Company Limited Announces Consolidated and Unconsolidated Earnings Results for the Full Year Ended March 31, 2018; Provides Earnings Guidance for the Fiscal Year 2019; Announces Year-End Dividend for the Fiscal Year Ended March 31, 2018, Payable on June 29, 2018; Provides Dividend Guidance for the First Half of 2019 and for the Fiscal Year Ending March 31, 2019

Takeda Pharmaceutical Company Limited announced consolidated and unconsolidated earnings results for the full year ended March 31, 2018, for the year, on the consolidated basis, the company's revenue was ¥1,770,531 million compared with ¥1,732,051 million a year ago. Operating profit was ¥241,789 million compared with ¥155,867 million a year ago. Profit before income taxes was ¥217,205 million compared with ¥143,346 million a year ago. Profit attributable to owners of the company was ¥186,886 million compared with ¥114,940 million a year ago. Diluted earnings per share were ¥237.56 compared with ¥146.26 a year ago. Return on equity attributable to owners of the company was 9.6% compared with 6.0% a year ago. Net cash from operating activities was ¥377,854 million compared with ¥261,363 million a year ago. Payments for acquisition of property, plant and equipment was ¥67,005 million compared with ¥61,660 million a year ago. Underlying Revenue was ¥88.9 billion, Underlying Core Earnings was ¥82.3 billion, and Underlying Core EPS was ¥86.16. For the fiscal year 2019, the company forecasts revenue of ¥1,737,000 million, core earnings of ¥309,500 million, operating profit of ¥201,000 million, profit before tax of ¥183,000 million and Net profit attributable to owners of the company of ¥139,000 million or ¥177.91 per share. For the year, on the unconsolidated basis, the company reported net sales of ¥659,462 million compared with ¥737,803 million a year ago. Operating income was ¥67,736 million compared with ¥70,262 million a year ago. Ordinary income was ¥125,944 million compared with ¥81,915 million a year ago. Net income was ¥187,004 million compared with ¥108,369 million a year ago. Diluted earnings per share were ¥239.18 compared with ¥138.60 a year ago. The company announced a year-end dividend of JPY 90.00 per share for the fiscal year ended March 31, 2018, compared with JPY 90.00 per share for the fiscal year ended March 31, 2017. The scheduled date of dividend payment commencement is June 29, 2018. The company expects to pay a dividend of JPY 90.00 per share for the end of first half of 2019. The company expects to pay a year-end dividend of JPY 90.00 per share for the fiscal year ending March 31, 2019.

Takeda Presents at 17th annual MIXiii-BIOMED 2018, May-15-2018 through May-17-2018

Takeda Presents at 17th annual MIXiii-BIOMED 2018, May-15-2018 through May-17-2018. Venue: David InterContinental Hotel, Tel Aviv, Israel. Presentation Date & Speakers: May-15-2018, Tauhid Ali, Vice President and Head of TAK-celerator.

Shire plc, Takeda Pharmaceutical Company Limited - M&A Call

To discuss Takeda Pharmaceutical Company Limited and Shire plc have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4502.
View Industry Companies
 

Industry Analysis

4502

Industry Average

Valuation 4502 Industry Range
Price/Earnings 18.3x
Price/Sales 1.9x
Price/Book 1.7x
Price/Cash Flow 11.0x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.